BULARREKO MINBIZIA
![Foto de BULARREKO MINBIZIA](/img/grupo.png)
![Foto de Hospital Vall d'Hebron](/img/noimage_org.png)
Hospital Vall d'Hebron
Barcelona, EspañaHospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (28)
2024
-
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
Breast, Vol. 77
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
2023
-
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma
British Journal of Cancer, Vol. 129, Núm. 5, pp. 811-818
-
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778
-
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4068-4075
2022
2020
-
Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients
Cancer Treatment Reviews, Vol. 83
-
MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Journal of Clinical Oncology, Vol. 38, Núm. 32, pp. 3753-3762
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Therapeutic Advances in Medical Oncology, Vol. 11
-
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 31-45
2018
-
Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME)
International Journal of Colorectal Disease, Vol. 33, Núm. 2, pp. 241-249
-
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Breast Cancer Research and Treatment, Vol. 168, Núm. 2, pp. 357-364
2017
-
Predictive and prognostic brain metastases assessment in luminal breast cancer patients: FN14 and GRP94 from diagnosis to prophylaxis
Frontiers in Oncology, Vol. 7, Núm. DEC
-
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
Stem Cell Reports, Vol. 8, Núm. 5, pp. 1392-1407
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
-
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89